Use of NGF growth factors to treat drug-induced neuropathy

Details Use of NGF growth factors to treat drug-induced neuropathy Use of NGF growth factors to treat drug-induced neuropathy

1993-11-17

1997-02-18

Schain, Howard E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 21, 530350, A61K 3800, A61K 5100

Patent

active

056042027

ABSTRACT:
This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor .varies. (TFG-.varies.), transforming growth factor .beta. (TGF-.beta.) and others to prevent drug-induced neuropathy.

REFERENCES:
patent: 4863902 (1989-09-01), Amagase
patent: 5073543 (1991-12-01), Marshall
Vinoreo et al., Cancer Research, 42(3), 1038-40, 1982, (abstract provided).
Camp et al. Vet. Pathol., 21(1), 67-73, 1984, (abstract provided.
Rakowicz-Szulczynska et al., Cancer Research, 48, 7200-7206, 1988.
Goretzki et al., Surgery, 102, 1035, 1987.
FDA Consumer, Annabel Hecht, staff writer for FDA's Office of Public Affairs, pp. 18, 20 and 21, 1977.
Burgess, British Medical Bulletin, 45, No. 2, 401-424, 1989.
Roberts et al., Proc. Natl. Acad. Sci. USA, 82, 119-123, 1985.
Marx, Jean; "NGF and Alzheimer's: Hopes and Fears;" Science, vol. 247; Jan. 26, 1990; pp. 408-410.
Mollman, Joan E.; "Cisplatin Neurotoxicity;" The New England Journal of Medicine; Jan. 11, 1990; pp. 126-127.
Lipton, R. B., et al.; "Taxol Produces a Predominantly Sensory Neuropathy;" Neurology; Mar. 1989; pp. 368-373.
Rakowicz-Szulczynska, Ewa M., et al.; "Nerve Growth Factor Receptors in Chromatin of Melanoma Cells, Proliferating Melanocytes, and Colorectal Carcinoma Cells in Vitro;" Cancer Research, 48; Dec. 15, 1988; pp. 7200-7206.
Yarchoan, Robert, et al.; "Phase I Studies of 2', 3'-Dideoxicytidine in Severe Human Immunodificiency Virus Infection as a Single Agent Alternating with Zidovudine (AZT);" The Lancet; Jan. 16, 1988, pp. 76-80.
Wiernik, Peter H., et al.; "Phase I Trial of Taxol Given as a 24-Hour Infusion Every 21 Days: Responses Observed in Metastatic Melanoma;" Journal of Clinical Oncology, vol. 5, No. 8; Aug. 1987; pp. 1232-1239.
Wiernik, Peter H., et al.; "Phase I Clinical and Pharmacokinetic Study of Taxol;" Cancer Research, 47; May 1, 1987; pp. 2486-2493.
Drubin, David G., et al.; "Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells Involves the Coordinate Induction of Microtubule Assembly and Assembly-Promoting Factors;" The Journal of Cell Biology, vol. 101; Nov. 1985; pp. 1799-1807.
Roytta, Matias, et al.; "Taxol-Induced Neuropathy: Short-Term Effects of Local Injection;" Journal of Neurocytology, 13; 1984; pp. 685-701.
Kessler, J. A., et al.; "Substance P and Somatostatin Metabolism in Sympathetic and Special Sensory Ganglia in Vitro;" Neuroscience, vol. 9, No. 2; 1983; pp. 309-318.
Peterson, Edith R., et al.; "Nerve Growth Factor Attenuates Neurotoxin Effects of Taxol on Spinal Cord-Ganglion Explants from Fetal Mice;" Science, vol. 217; Jul. 23, 1982; pp. 377-379.
Schiff, Peter B., et al.; "Taxol Stabilizes Microtubules in Mouse Fibroblast Cells"; Proc. Natl. Acad. Sci., vol. 77, No. 3; Mar. 1980, pp. 1561-1565.
Kessler, John A., et al.; "Nerve Growth Factor Stimulates the Development of Substance P in Sensory Ganglia;" Proc. Natl. Acad. Sci., vol. 77, No. 1; Jan. 1980; pp. 649-652.
Schiff, Peter B., et al.; "Promotion of Microtubule Assembly in Vitro by Taxol;" Nature, vol. 277; Feb. 22, 1979; pp. 665-667.
Henry, James L.; "Effects of Substance P on Functionally Identified Units in Cat Spinal Cord;" Brain Research, 114; 1976; pp. 439-451.
Mobley, William C., et al.; "Characterization and Isolation of Proteolytically Modified Nerve Growth Factor;" Biochemistry, vol. 15, No. 25; 1976; pp. 5543-5552.

Affiliated with

Also associated with

Rating

Use of NGF growth factors to treat drug-induced neuropathy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of NGF growth factors to treat drug-induced neuropathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of NGF growth factors to treat drug-induced neuropathy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1602551